By Fineline Cube 
Novo Nordisk A/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for two formulations of Wegovy (semaglutide) for obesity treatment: the 7.2 mg single-dose pen and the once-daily oral tablet (25 mg).
Regulatory Milestones & Product Portfolio
| Product | Formulation | Current EU Status | Global Availability | Expected EU Launch |
|---|---|---|---|---|
| Wegovy 7.2 mg | Once-weekly injectable single-dose pen | CHMP positive opinion | Approved in US (as Wegovy HD) and UK | Q3 2026 |
| Wegovy pill | Once-daily oral semaglutide 25 mg | CHMP positive opinion | Not yet available outside US | H2 2026 (select markets) |
Clinical Evidence & Efficacy Data
STEP UP Trial Programme – Wegovy 7.2 mg Injection
- Mean Weight Loss: 20.7% in participants with obesity
- Dosing Regimen: Once-weekly 7.2 mg injection (single-dose pen)
- Comparison: Previously available as three separate 2.4 mg injections totaling 7.2 mg weekly dose
OASIS & SELECT Trial Programmes – Wegovy Oral Tablet
- Weight Loss Efficacy: Comparable to injectable Wegovy 2.4 mg
- Cardiovascular Benefits: SELECT trial data demonstrates significant reduction in major adverse cardiovascular events (MACE)
- Label Inclusion: CHMP positive opinion includes SELECT cardiovascular risk reduction data in product labeling
Market Expansion Strategy
Novo Nordisk’s dual-track approach addresses different patient preferences and treatment adherence challenges:
- Injectable 7.2 mg pen: Simplifies administration compared to previous multi-injection regimen
- Oral 25 mg tablet: Offers needle-free option with proven efficacy equivalent to established injectable doses
The company plans a phased EU rollout beginning with the injectable formulation in Q3 2026, followed by oral tablet launch in select international markets in the second half of 2026. The inclusion of cardiovascular risk reduction data in the oral formulation’s label represents a significant competitive advantage, positioning Wegovy as both a weight management and cardiovascular protective therapy.
Competitive Landscape & Commercial Impact
With obesity affecting over 59 million adults in the EU, Novo Nordisk’s expanded Wegovy portfolio addresses a substantial unmet medical need. The 20.7% mean weight loss demonstrated by the 7.2 mg formulation significantly exceeds results from competing GLP-1 therapies, while the oral option removes a key barrier to treatment initiation.
The cardiovascular benefits validated in the SELECT trial further differentiate Wegovy from competitors lacking robust outcome data, potentially influencing reimbursement decisions and clinical guidelines across European healthcare systems.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, product launches, clinical outcomes, and commercial expectations. Actual results may differ due to risks including final regulatory decisions, market competition, manufacturing capacity, and pricing negotiations.-Fineline Info & Tech